“We congratulate Secretary Price on today’s confirmation and look forward to working with his team, President [Donald] Trump and both parties in Congress to ensure that generic medicines continue to keep treatments within reach of all Americans,” Davis said in his statement.
Davis noted that Price spoke of the importance of generic drugs in America’s health care system and should be critical to the new administration.
“As the president and his administration rightly focus on addressing the cost of prescription drugs, it provides a great opportunity to increase generic competition in the pharmaceutical market, saving lives and saving money,” Davis said. “That’s a win-win for our country and our health care system, and we’re anxious to work with the administration and Congress to get the job done."
AAM, formerly known as GPhA, represents the manufacturers and distributors of finished generic pharmaceuticals.